Miraklide (Escitalopram)

Escitalopram, the active ingredient in Miraklide, is a selective serotonin reuptake inhibitor presented as an oral tablet for oral use. It is prescribed for several mood and anxiety disorders in adult patients. GNH USA supplies Miraklide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Escitalopram is an SSRI that modulates serotonin pathways and is indicated for the following conditions: - Major depressive disorder: alleviates depressive symptoms and improves mood. - Generalized anxiety disorder: reduces excessive worry and physical tension. - Panic disorder: decreases frequency and severity of panic attacks. - Social anxiety disorder: lessens fear of social situations and improves functioning.

Escitalopram may cause a range of adverse reactions. Patients should be informed of both common and serious possibilities.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient tension‑type headaches. - Insomnia: difficulty falling or staying asleep. - Dry mouth: reduced salivation. - Sexual dysfunction: decreased libido or difficulty achieving orgasm. - Dizziness: light‑headed sensation, especially on standing.

Serious or Rare Side Effects: - Serotonin syndrome: agitation, hyperthermia, muscle rigidity. - Suicidal thoughts: emergence of suicidal ideation, particularly early in treatment. - Severe allergic reaction: rash, swelling, or breathing difficulty. - QT interval prolongation: cardiac rhythm disturbances. - Hyponatremia: low blood sodium causing confusion or seizures. - Abnormal bleeding: increased bruising or prolonged bleeding.

Before initiating therapy, clinicians should consider several safety aspects. - Assess for suicidal ideation: monitor patients closely during the first weeks. - Evaluate hepatic function: dose adjustment may be needed in severe impairment. - Review concomitant serotonergic agents: avoid combinations that increase serotonin syndrome risk. - Caution in elderly: higher incidence of hyponatremia and falls. - Pregnancy and lactation: discuss potential risks with the prescriber. - Store below 25°C: keep in the original pack, protect from moisture.

Escitalopram can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Pimozide or thioridazine: can cause QT prolongation. - Linezolid: additive serotonergic effect. - Other serotonergic agents (e.g., tramadol, triptans): increase serotonin syndrome risk.

Moderate Interactions (Monitor Closely): - NSAIDs or anticoagulants: heightened bleeding tendency. - CYP2C19 inhibitors (e.g., fluoxetine, omeprazole): may raise escitalopram levels. - CYP3A4 inhibitors (e.g., ketoconazole): modest increase in exposure. - Alcohol: may exacerbate CNS depression. - Antihistamines: potential additive sedation.